---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002786"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:37:01.524159+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q4 revenue $55.2M (+46% YoY); guides FY2023 rev $205M-$215M

## Summary
- Full year 2022 revenue $185.3M (+20% YoY); MRD revenue $87.1M (+32%), Immune Medicine $98.2M (+11%).
- clonoSEQ test volume Q4 up 54% to 10,526 tests; full year up 51% to 36,871 tests.
- Net loss Q4 $40.2M vs $61.4M; adjusted EBITDA loss $19.6M vs $44.9M YoY.
- 2023 revenue guidance $205M-$215M; operating expenses expected below $385.5M.
- Long-term targets: 20-30% revenue CAGR, positive adjusted EBITDA in 2025, cash flow breakeven in 2026.

## SEC filing metadata
- accession: 0000950170-23-002786
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/adpt-20230214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002786
- JSON: https://secwatch.observer/filing/0000950170-23-002786.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002786.txt

## Key facts
- Earnings Releases
  Adaptive Biotechnologies Corp reported full year 2023 results: revenue $205 million to $215 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: $205 million to $215 million
  - Guidance: initiated
  - Result: guidance update
  source text: Adaptive Biotechnologies expects full year 2023 revenue to be in the range of $205 million to $215 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm
- Earnings Releases
  Adaptive Biotechnologies Corp reported full year ended December 31, 2022 results: revenue $185.3 million, net income Net loss was $200.4 million.
  - Period: full year ended December 31, 2022
  - Revenue: $185.3 million
  - Net income: Net loss was $200.4 million
  - Result: reported results
  source text: Revenue was $185.3 million for the year ended December 31, 2022, representing a 20% increase from the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm
- Earnings Releases
  Adaptive Biotechnologies Corp reported fourth quarter ended December 31, 2022 results: revenue $55.2 million, net income Net loss was $40.2 million.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: $55.2 million
  - Net income: Net loss was $40.2 million
  - Result: reported results
  source text: Revenue was $55.2 million for the quarter ended December 31, 2022, representing a 46% increase from the fourth quarter in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.